"7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: Are they still effective? a randomized trial"

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 3, 2011, Pages 407-412

  Karatapanis, S ^a   Georgopoulos, S D ^b   Papastergiou, V ^a   Skorda, L ^a   Papantoniou, N ^c   Lisgos, Ph ^a   Kouvidou, C ^d   Fragkou, P ^a   Mentis, A ^e  

^a General Hospital of Rhodes   (Greece)

^b ATHENS MEDICAL CENTER   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d KAT HOSPITAL   (Greece)

^e HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

Greece; Helicobacter pylori; Rabeprazole; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; RABEPRAZOLE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PROTOCOL; DIARRHEA; DNA POLYMORPHISM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GREECE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80053598367     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. KUIPER E.J. Helicobacter pylori and the risk and management of associated diseases: gastritis, gastric ulcer, atrophic gastritis and gastric cancer. Alim. Pharmacol. Ther., 1997, 11 (Suppl): 71-88.
2. CURRENT EUROPEAN CONCEPTS IN THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut, 1997, 41: 8-13.
3. HOWDEN C.W., HUNT R.H. Guidelines for the management of Helicobacter pylori infection. Ad hoc committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol., 1998, 93: 2330-2338.
4. MALFERTHEINER P., MEGRAUD F., O'MORAIN C., BAZZOLI F., EL-OMAR E., GRAHAM D., HUNT R., ROKKAS T., VALIL N., KUIPERS E.J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 2007, 56: 772-781.
5. MALFERTHEINER P., MEGRAUD F., O'MORAIN C., HUNGIN AP., JONES R., AXON A., GRAHAM DY., TYTGAT G. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus report. Alim. Pharmacol. Ther., 2002, 16: 167-86.
6. DE FRANCESCO V., ZULLO A., HAASAN C., DELLA VALLE N., PIETRINI L., MINENNA MF., WINN S., MONNO R., STOPPINO V., MORINI S., PANELLA C., LERARDI E. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig. Liver Dis., 2004, 36: 322-326.
7. YAMAOKA Y., GRAHAM D.Y., LU H. Should triple therapy for Helico - bacter pylori be abandoned as no longer effective. US Gastroenterology, 2008, 65-67.
8. GRAHAM D.Y. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepato., 2009, 7: 145-148.
9. GISBERT J.P., CALVET X., O'CONNOR A., MÉGRAUD F., O'MORAIN C.A. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol., 2010, 44: 313-332.
10. VALKI N., MEGRAUD F. Eradication therapy for Helicobacter pylori. Gastroenterology, 2007, 133: 985-1001.
11. BUZÀS G.M. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J. Gastroenterol., 2010, 16: 3865-3870.
12. ZULLO A., VAIRA D., VAKIL N HASSAN C., GATTA L., RICCI C., DE FRANCESCO V., MENEGATTI M., TAMPIERI A., PERNA F., RINALDI V., PERRI F., PAPADÌA C., FORNARI F., PILATI S., METE L.S., MERLA A., POTÌ R., MARINONE G., SAVIOLI A., CAMPO SM., FALEO D., IERARDI E., MIGLIOLI M., MORINI S. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther., 2003, 17: 719-726.
13. WILLIAMS M.P., POUNDER R.E. Review article: the pharmacology of rabeprazole. Aliment. Pharmacol. Ther., 1999, 13 (Suppl. 3): 3-10.
14. STEDMAN C.A., BARCLAY M.L. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther., 2000, 14: 963-978.
15. ZHAO F., WANG J., YANG Y., WANG X., SHI R., XU Z., HUANG Z., ZHANG G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter, 2008, 13: 532-541.
16. HUANG J.Q., HUNT R.H. Treatment after failure: the problem of "nonresponders". Gut, 1999, 46 (Suppl 1): 140-144.
17. PERRI F., VILLANI M.R., FESTA V., QUITADAMO M., ANDRIULLI A. Predictors of failure of Helicobacter pylori eradication with the standard'Maastricht triple therapy'. Aliment. Pharmacol. Ther., 2001, 15: 1023-1029.
18. FISCHBACH L.A., GOODMAN K.J., FELDMAN M., ARAGAKI C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int. J. Epidemiol., 2002, 31: 128-139.
19. NASH C., FISCHBACH L., VELDHUYZEN VAN ZANTEN S. What are the global response rates to Helicobacter pylori eradication therapy? Can. J. Gastroenterol., 2003, 17 Suppl B: 25B-29B.
20. BROUTET N., TCHAMGOUE S., PEREIRA E., LAMOULIATTE H., SALAMON R., MEGRAUD F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther., 2003, 17: 99-109.
21. GEORGOPOULOS S.D., LADAS S.D., KARATAPANIS S., MENTIS A., SPILIADI C., ARTIKIS V., RAPTIS S.A. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole amoxicilline and clarithromycin. Dig. Dis. Sci., 2000, 45: 63-67.
22. MENTIS A., ROMA E., PANGALIS A., KATSIYANNAKIS E. Antibiotic susceptibility of Helicobacter pylori strains isolated from children with gastritis. J. Antimicrob. Chemother., 1999, 44: 720-722.
23. GLUPCZYNSKI Y., MEGRAUD F., LOPEZ-BREA M., ANDERSEN L.P. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis., 2001, 20: 820-823.
24. BOYANOVA L., MENTIS A., GUBINA M., ROZYNEK E., GOSCINIAK G., KALENIC S., GÖRAL V., KUPCINSKAS L., KANTARÇEKEN B., AYDIN A., ARCHIMANDRITIS A., DZIERZANOWSKA D., VCEV A., IVANOVA K., MARINA M., MITOV I., PETROV P., OZDEN A., POPOVA M. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin. Microbiol. Infect., 2002, 8: 388-396.
25. KOLETZKO S., RICHY F., BONTEMS P., CRONE J., KALACH N., MONTEIRO M.L., GOTTRAND F., CELINSKA-CEDRO D., ROMA-GIANNIKOU E., ORDERDA G., KOLACEK S., URRUZUNO P., MARTÍNEZ-GÓMEZ M.J., CASSWALL T., ASHORN M., BODANSZKY H., MÉGRAUD F. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut, 2006, 55: 1711-1716.
26. COENEN S., FERECH M., MALHOTRA-KUMAR S., HENDRICKX E., SUETENS C., GOOSENS H., ESAC PROJECT GROUP. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J. Antimicrob. Chemother., 2006, 58: 418-422.
27. DE FRANCESCO V., MARGIOTTA M., ZULLO A., HASSAN C., GIORGIO F., BURATTINI O., STOPPINO G., CEA U., PACE A., ZOTTI M., MORINI S., PANELLA C., IERARDI E. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J. Antimicrob. Chemother., 2007, 59: 783-785.
28. ONDER G., AYDIN A., AKARCA U., TEKIN F., OZUTEMIZ O., ILTER T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J. Clin. Gastroenterol., 2007, 41: 747-750.
29. SUGIMOTO M., FURUTA T., SHIRAI N., KODAIRA C., NISHINO M., IKUMA M., ISHIZAKI T., HISHIDA A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter, 2007, 12: 317-323.
30. FURUTA T., SHIRAI N., TAKASHIMA M., XIAO F., HANAI H., SUGIMURA H., OHASHI K., ISHIZAKI T., KANEKO E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithro - mycin. Clin. Pharmacol. Ther., 2001, 69: 158-168.
31. N., FURUTA T., MORIYAMA Y., OKOCHI H., KOBAYASHI K., TAKASHIMA M., XIAO F., KOSUGE K., NAKAGAWA K., HANAI H.,CHIBA K., OHASHI K., ISHIZAKI T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther., 2001, 15: 1929-1937.
32. K., KATSUBE T., KAWAMURA., TAKASHIMA T., YUKI M., AMANO K., ISHIHARA S., FUKUDA R., WATANABE M., KINOSHITA Y. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther., 2000, 14: 1259-1266.
33. SAITOH T., FUKUSHIMA Y., OTSUKA H., HIRAKAWA J., MORI H., ASANO T., ISHIKAWA T., KATSUBE T., OGAWA K., OHKAWA S. Effects of rabeprazole, lansoprazole, and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther., 2002, 16: 1811-1817.
34. SASAKI M., OGASAWARA N., UTSUMI K., KAWAMURA N., KAMIYA T., KATAOKA H., TANIDA S., MIZOSHITA T., KASUGAI K., JOH T. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J. Clin. Biochem. Nutr., 2010, 4: 53-58.
35. SUZUKI H., MIYAZAWA M., NAGAHASHI S., SATO M., BESSHO M., NAGATA H., MIURA S., ISHII H. Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils. J. Gastroenterol. Hepatol., 2003, 18: 787-795.
36. CALVET X., GARCIA N., LOPEZ T., GISBERT J.P., GENÈ E., ROCQUE M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther., 2000, 14: 603-609.
37. CALVET X., DUCONS J., BUJANDA L., BORY F., MONTSERRAT A., GISBERT J.P. Seven versus Ten Days of Rabeprazole Triple Therapy for Helicobacter pylori Eradication: A Multicenter Randomized Trial. Am. J. Gastroenterol., 2005, 100: 1696-1701.
38. VAKIL N., LANZA F., SCHWARTZ H., BARTH J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther., 2004, 20: 99-107.